Health Trials

About this trial

Post-market, prospective, non randomized, open label, multicentre, clinical study analysing outcomes of shoulder arthroplasty with SMR TT Hybrid Glenoid with or without SMR Cementless Finned Short Stem

Eligibility criteria

Qualifiers

Both genders;

Age ≥ 18 years old;

Full skeletal maturity;

Life expectancy over 5 years;

Disqualifiers

Patient requiring revision shoulder arthroplasty;

Osteoporosis with a history of non-traumatic fractures;

Steroid injections within the previous 3 months;

Contralateral shoulder replacement within the previous 3 months;

Trial design

Treatments tested in this trial

  • SMR TT Hybrid Glenoid without Cementless Finned Short Stem
  • SMR TT Hybrid Glenoid with Cementless Finned Short Stem

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Limacorporate S.p.a

Lead sponsor

Source ClinicalTrials.gov